A phase II clinical trial of Sargramostim in patients with sepsis
Latest Information Update: 19 Jan 2025
Price :
$35 *
At a glance
- Drugs Sargramostim (Primary)
- Indications Sepsis
- Focus Adverse reactions
- 16 Jan 2025 New trial record
- 09 Jan 2025 According to a Partner therapeutics media release, the company announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to fund a phase 2 study in patients with sepsis to assess the safety and enable dose selection of LEUKINE (sargramostim, rhu GM-CSF).